HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2024-2028

The HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market size is estimated to grow by USD 11,066.53 million at a CAGR of 9.94% between 2023 and 2028. 

The global human epidermal growth factor receptor 2 (HER2) inhibitors market has been propelled by continual development in R&D efforts. Treatment choices have been greatly increased, and patient outcomes have improved as a result of the discovery of more potent HER2 inhibitors through R&D initiatives. Notably, the landscape of HER2-positive breast and gastric cancer therapy has been revolutionized by more recent monoclonal antibodies and targeted medicines. Moreover, when combined with trastuzumab, the monoclonal antibody pertuzumab has demonstrated improved inhibition of HER2-positive tumour cell proliferation. Additionally, continuing R&D projects concentrate on reducing adverse effects, enhancing drug delivery systems, and investigating novel medication combinations, assuring a constant influx of cutting-edge HER2 inhibitors. Such factors will increase the demand for HER2 inhibitors, thereby driving the growth of the market during the forecast period.

Technavio has segmented the market into product, distribution channel, and geography 

• The product segment is classified into monotherapy and combination therapy
• The distribution channel segment is classified into retail pharmacies, hospital pharmacies, and online pharmacies
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.

What will be the Size of the HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market During the Forecast Period?

To learn more about this report, Request Free Sample

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Segmentation by Product, Distribution Channel and Geography Analysis

Product Analysis

Monotherapy  

The market share growth by the monotherapy segment will be significant during the forecast period. Monotherapy is the use of a single drug candidate to treat a disease or condition. The monotherapy segment of the her2 (Human Epidermal Growth Factor Receptor 2) inhibitors market is smaller than the combination therapy segment, as drugs in combination are used more than the use of a single drug. 

Get a glance at the market contribution of various segments View a PDF Sample

The monotherapy segment was the largest and was valued at USD 9,350.57 million in 2018. Furthermore, the cost of the treatment using monotherapy is less compared with that using combination therapy in the short run. However, research is witnessing a shift toward the development of various combination therapy options. Thus, the high cost of the treatment type and the increasing competition from the combination therapy segment can limit the growth of the monotherapy segment to some extent during the forecast period. However, the monotherapy segment of the her2 (Human Epidermal Growth Factor Receptor 2) inhibitors market is likely to retain its dominant position during the forecast period, owing to the presence of blockbuster drugs. Despite the dominant position, this segment is expected to grow at a slower rate than that of the combination therapy segment during the same period.

Distribution Channel Analysis

Retail pharmacies

In the global human epidermal growth factor receptor 2 (HER2) inhibitors market, retail pharmacies have become an essential distribution channel. Numerous important elements have contributed to this expansion. The ability for patients to receive consultations and prescriptions remotely during the COVID-19 pandemic has accelerated the adoption of retail pharmacy distribution for prescription medications, including HER2 inhibitors. This distribution channel is positioned to play an increasingly important role in the human epidermal growth factor receptor 2 inhibitors market due to the ongoing improvements in oncology therapies and the convenience of retail pharmacy networks. This, in turn, will drive the growth of the market in focus during the forecast period.

Hospital pharmacies

Hospital pharmacies have recently emerged as a significant player in the global human epidermal growth factor receptor 2 (HER2) inhibitors market, which is characterized by significant shifts in the distribution channelsHospital pharmacies are an excellent alternative for preserving product integrity and compliance because HER2 inhibitors are subject to strict restrictions and storage requirements. Additionally, hospital pharmacies are positioned to play an increasingly important role in assuring prompt access to these life-saving treatments as global demand for HER2 inhibitors continues to grow, which will be advantageous for both patients and the pharmaceutical industry. Owing to these factors, the market in focus is expected to witness significant growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The growth of the human epidermal growth factor receptor 2 inhibitors market in this region is primarily driven by the sales of approved HER2 inhibitors and the growing prevalence of several carcinomas that are caused by overexpressing HER2 protein. These cancers include HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma and non-small cell lung cancer (NSCLC), along with breast cancer. For instance, more than 200,000 cases of breast cancer are diagnosed in the US each year, and HER2-positive breast cancer accounts for a significant share of it.

Furthermore, the Centers for Disease Control and Prevention (CDC) states that more than 28.5 million invasive cancer cases have been diagnosed since 2000. Such a high prevalence of cancer demands advanced and specialized treatment options. Targeted therapies, such as HER2 inhibitors, have the potential to meet this requirement. Hence, the high prevalence of HER2-overexpressing carcinomas is expected to drive the growth of the market in North America during the forecast period.

COVID Recovery Analysis

The COVID-19 pandemic significantly affected the North American human epidermal growth factor receptor 2 (HER2) inhibitors market in 2020. However, a favorable change was brought about in 2021 by the widespread administration of the COVID-19 vaccine in the region. Healthcare systems progressively resumed regular operations as rates of vaccinations rose. The human epidermal growth factor receptor 2 (HER2) inhibitors market grew in 2021 and 2022 as a result of greater patient confidence, prompt diagnosis, and strong regulatory agency backing. Companies like Roche and AstraZeneca will profit from these favorable trends. As a result, the regional market in focus is expected to drive the growth of the market in focus during the forecast period.

Buy Now Full Report and Discover More

Key HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Amgen Inc. - The company offers HER2 inhibitors to bind an extracellular ligand and activate several intracellular pathways that contribute to cell proliferation, apoptosis, adhesion, migration, and differentiation.

• AryoGen Pharmed
• AstraZeneca Plc
• Biocon Ltd.
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Intas Pharmaceuticals Ltd.
• JSC BIOCAD
• MacroGenics Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Puma Biotechnology Inc.
• Samsung Biologics Co. Ltd.
• Shanghai Henlius Biotech Inc.
• Viatris Inc.
• Celltrion Healthcare Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Drivers

Growing awareness about breast cancer is notably driving the market growth. Regular breast cancer screening is important as many women with breast cancer do not exhibit symptoms. The delay in the diagnosis of breast cancer can cause severe problems in patients. At times, it can even lead to death. Therefore, awareness about the diagnosis and treatment options is important to get the right treatment at the right time. Furthermore, the World Health Organization (WHO) promotes comprehensive breast cancer control programs as part of its national cancer control plans.

Moreover, the increasing number of awareness campaigns on breast cancer is leading to a rise in the early diagnosis of the disease, and the treatment using therapeutics is highly effective in the early stages of this indication. Thus, the growing awareness about breast cancer is expected to propel the growth of the market during the forecast period.

Significant HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Trends

Patient assistance programs is an emerging trend shaping the market growth. Currently, HER2 inhibitors are available at high costs, which makes it difficult for patients to purchase them. Hence, the low adoption of high-cost HER2 inhibitors can adversely affect their sales. Pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden on patients. For instance, Pfizer has introduced Pfizer Oncology Together, a program that offers personalized support to patients. With this program, eligible, commercially insured patients do not have to pay for VIZIMPRO.

Similarly, Puma Biotechnology introduced a co-pay assistance program, Puma Patient Lynx, to help qualified, insured patients with the out-of-pocket costs associated with NERLYNX. Through this program, commercially insured, eligible patients treated with NERLYNX can pay as little as USD 10 per prescription. Such patient assistance programs will increase patient adherence to HER2 inhibitors, which will drive the growth of the market during the forecast period.

Major HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Challenges

Development of resistance or tolerance to HER2 inhibitors over time is a significant challenge hindering market growth. A major challenge for the human epidermal growth factor receptor 2 inhibitors market in focus is the emergence of HER2 inhibitor tolerance or resistance. These medications may become less effective over time for some people with malignancies that are HER2-positive. This phenomenon emphasizes the necessity for continual investigation and creativity to develop novel therapeutic approaches that can get beyond patient resistance and improve patient outcomes. Government organizations, such as the National Cancer Institute in the US, spend significant research funds to tackle this problem, highlighting the need to discover cutting-edge methods to overcome resistance.

Despite these initiatives, dealing with resistance is still a difficult task that affects patients as well as the pharmaceutical industry. Hence, resistance and tolerance are expected to hinder the growth of the global human epidermal growth factor receptor 2 (HER2) inhibitors market during the forecast period.

Buy Now Full Report and Discover More

Key HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Customer Landscape

Segment Overview

The HER2 (human epidermal growth factor receptor 2) inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

•  Product Outlook (USD Million, 2018 - 2028)
  • Monotherapy
  • Combination therapy

•  Distribution Channel Outlook (USD Million, 2018 - 2028)
  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

• Region Outlook (USD Million, 2018 - 2028)
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest Of World (ROW)
    • Brazil
    • Argentina
    • Australia

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Scope
Report Coverage	Details
Page number	164
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 9.94%
Market Growth 2024-2028	USD 11,066.53 million
Market structure	Fragmented
YoY growth 2023-2024(%)	8.9
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 45%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., AryoGen Pharmed, AstraZeneca Plc, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., JSC BIOCAD, MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Samsung Biologics Co. Ltd., Shanghai Henlius Biotech Inc., Viatris Inc., and Celltrion Healthcare Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market  between 2024 and 2028
• Precise estimation of the her2 (human epidermal growth factor receptor 2) inhibitors market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of her2 (human epidermal growth factor receptor 2) inhibitors market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch